Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2008 May;52(5):1653-62. doi: 10.1128/AAC.01383-07. Epub 2008 Mar 3.

In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.

Author information

1
Rib-X Pharmaceuticals, Inc., 300 George Street, New Haven, Connecticut 06511, USA.

Abstract

Rx-01_423 and Rx-01_667 are two members of the family of oxazolidinones that were designed using a combination of computational and medicinal chemistry and conventional biological techniques. The compounds have a two- to eightfold-improved potency over linezolid against serious gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant streptococci, and vancomycin-resistant enterococci. This enhanced potency extends to the coverage of linezolid-resistant gram-positive microbes, especially multidrug-resistant enterococci and pneumococci. Compounds from this series expand the spectrum compared with linezolid to include fastidious gram-negative organisms like Haemophilus influenzae and Moraxella catarrhalis. Like linezolid, the Rx-01 compounds are bacteriostatic against MRSA and enterococci but are generally bactericidal against S. pneumoniae and H. influenzae.

PMID:
18316525
PMCID:
PMC2346622
DOI:
10.1128/AAC.01383-07
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center